Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
26 papers
Recent·Most cited
F. Zhang, F. Schmidt, F. Muecksch, Z. Wang, A. Gazumyan, M. C. Nussenzweig, C. Gaebler, M. Caskey, T. Hatziioannou, P. D. Bieniasz
This study examines how SARS-CoV-2 spike glycosylation affects viral function and neutralization sensitivity to antibodies.
bioRxiv · Jun 30, 2023Microbiology
L. Yang, M. Van Beek, Z. Wang, F. Muecksch, M. Canis, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, A. K. Chakraborty
The paper shows that antigen presentation dynamics after multiple vaccinations influence the immune response to SARS-CoV-2 Omicron by shaping B cell responses and antibody targeting of epitopes.
bioRxiv · Aug 24, 2022Immunology
L. Witte, V. Baharani, F. Schmidt, Z. Wang, A. Cho, R. Raspe, M. C. Guzman-Cardozo, F. Muecksch, C. Gaebler, M. Caskey, M. C. Nussenzweig, T. Hatziioannou, P. D. Bieniasz
The paper shows that epistasis reduces the genetic barrier for SARS-CoV-2 variants to escape broadly neutralizing antibodies by enabling resistance through combinations of mutations.
bioRxiv · Aug 17, 2022Microbiology
Z. Wang, P. Zhou, F. Muecksch, A. Cho, T. B. Tanfous, M. Canis, L. Witte, B. Johnson, R. Raspe, F. Schmidt, E. Bednarski, J. DaSilva, V. Ramos, S. Zong, M. Turroja, , M. C. Nussenzweig
This study compares memory B cell responses after Delta and Omicron BA.1 breakthrough infections versus mRNA vaccine doses, finding that Delta infection boosts overall memory B cell potency and breadth, while Omicron infection only enhances strain-specific responses.
bioRxiv · Aug 11, 2022Immunology
Z. Wang, F. Muecksch, F. Muenn, A. Cho, S. Zong, R. Raspe, V. Ramos, B. Johnson, T. B. Tanfous, J. DaSilva, E. Bednarski, C. Guzman-Cardozo, P. Tober-Lau, D. Hillus, K. Yao, , C. Gaebler
This study compares humoral immune responses to different SARS-CoV-2 vaccination regimens, finding differences in antibody and memory B cell responses and neutralizing breadth against variants.
bioRxiv · May 13, 2022Immunology
A. Cho, F. Muecksch, Z. Wang, T. Ben Tanfous, J. DaSilva, R. Raspe, B. Johnson, E. Bednarski, V. Ramos, D. Schaefer-Babajew, I. Shimeliovich, J. Dizon, K.-H. Yao, F. Schmidt, K. G. Millard, , M. C. Nussenzweig
This study compares memory B cell responses after single-dose Ad26.COV2.S and mRNA vaccines, finding lower quantities but comparable neutralizing quality in Ad26.COV2.S recipients.
bioRxiv · Mar 31, 2022Immunology
F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. Ben Tanfous, J. DaSilva, E. Bednarski, V. Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I. Shimeliovich, M. Daga, K.-H. Yao, , M. Nussenzweig
This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.
bioRxiv · Feb 14, 2022 · PreprintImmunology
Z. Wang, F. Muecksch, A. Cho, C. Gaebler, H.-H. Hoffmann, V. Ramos, S. Zong, M. Cipolla, B. Johnson, F. Schmidt, J. DaSilva, E. Bednarski, T. B. Tanfous, R. Raspe, K. Yao, , M. C. Nussenzweig
The paper identifies conserved neutralizing epitopes on the N-terminal domain of SARS-CoV-2 spike proteins using NTD-specific probes and characterizes antibodies that neutralize multiple variants.
bioRxiv · Feb 1, 2022 · PreprintImmunology
A. Cho, F. Muecksch, D. Schaefer-Babajew, Z. Wang, S. Finkin, C. Gaebler, V. Ramos, M. Cipolla, P. Mendoza, M. Agudelo, E. Bednarski, J. DaSilva, I. Shimeliovich, J. Dizon, M. Daga, , M. C. Nussenzweig
This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.
bioRxiv · Jul 29, 2021Immunology
Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig
This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.
Nature · Jun 14, 2021Peer-reviewedImmunology
C. A. Jette, A. A. Cohen, P. N. P. Gnanapragasam, F. Muecksch, Y. E. Lee, K. E. Huey-Tubman, F. Schmidt, T. Hatziioannou, P. D. Bieniasz, M. C. Nussenzweig, A. P. West, J. R. Keeffe, P. Bjorkman, C. O. Barnes
The paper identifies two class 4 anti-RBD antibodies from COVID-19 donors that broadly neutralize zoonotic sarbecoviruses and SARS-CoV-2 variants with high potency.
bioRxiv · Apr 23, 2021Immunology
E. R. Kastenhuber, J. A. Jaimes, J. L. Johnson, M. Mercadante, F. Muecksch, Y. Weisblum, Y. Bram, R. E. Schwartz, G. R. Whittaker, L. C. Cantley
This study shows coagulation factors like factor Xa and thrombin directly cleave SARS-CoV-2 spike, enhancing viral entry, and suggests anticoagulation could reduce infection.
bioRxiv · Mar 31, 2021Microbiology
A. J. Greaney, T. N. Starr, C. O. Barnes, Y. Weisblum, F. Schmidt, M. Caskey, C. Gaebler, M. Agudelo, S. Finkin, Z. Wang, D. Poston, F. Muecksch, T. Hatziioannou, P. D. Bieniasz, D. F. Robbiani, , J. D. Bloom
The paper maps mutations in SARS-CoV-2 spike RBD that escape binding by three antibody classes and finds that plasma escape maps closely resemble those of a single antibody class targeting site E484.
bioRxiv · Mar 17, 2021Microbiology
F. Muecksch, Y. Weisblum, C. Barnes, F. Schmidt, D. Schaefer-Babajew, J. Lorenzi, A. Flyak, A. DeLaitsch, K. Huey-Tubman, S. Hou, C. Schiffer, C. Gaebler, Z. Wang, J. Da Silva, D. Poston, , P. Bieniasz
This study examines how somatic mutations in SARS-CoV-2 antibodies affect their neutralization potency, breadth, and resistance to escape mutations across six antibody lineages.
bioRxiv · Mar 7, 2021 · PreprintMicrobiology
J. Xu, K. Xu, S. K. Jung, A. Conte, J. Lieberman, F. Muecksch, J. C. C. Lorenzi, S. Park, Z. Wang, L. Tessarollo, T. Bylund, G.-Y. Chuang, A. Olia, I.-T. Teng, T. Zhou, , R. Casellas
This paper isolates and characterizes nanobodies from camelids and engineered mice that neutralize SARS-CoV-2 variants through conserved epitopes and multimeric avidity.
bioRxiv · Mar 4, 2021 · PreprintImmunology
Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C. O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J. A. Lieberman, T. Y. Oliveira, Z. Yang, M. E. Abernathy, K. E. Huey-Tubman, A. Hurley, , M. C. Nussenzweig
This study examines antibody and memory B cell responses to mRNA vaccines against SARS-CoV-2 and assesses their effectiveness against emerging variants.
Nature · Feb 10, 2021Peer-reviewedImmunology
R. De Gasparo, M. Pedotti, L. Simonelli, P. Nickl, F. Muecksch, I. Cassaniti, E. Percivalle, J. C. C. Lorenzi, F. Mazzola, D. Magri, T. Michalcikova, J. Haviernik, V. Honig, B. Mrazkova, N. Polakova, , T. Hatziioannou
bioRxiv · Jan 22, 2021 · PreprintImmunology
G. Baisa, D. Rancour, K. Mansfield, M. Burns, L. Martin, D. Cunha, J. Fischer, F. Muecksch, T. Hatziioannou, P. Bieniasz, F. Schomburg, K. Luke
This study evaluates a recombinant SARS-CoV-2 vaccine in macaques, showing that antigens from the RBD elicit high-titer neutralizing antibodies lasting over 20 weeks.
bioRxiv · Dec 20, 2020 · PreprintImmunology
C. Gaebler, Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, M. Tokuyama, A. Cho, M. Jankovic, D. Schaefer-Babajew, T. Y. Oliveira, M. Cipolla, C. Viant, C. O. Barnes, A. Hurley, M. Turroja, , R. Patel
This study examines the evolution of antibody immunity to SARS-CoV-2 over time, finding that memory B cells evolve with increased potency and resistance to mutations.
bioRxiv · Nov 3, 2020Immunology
A. Schaefer, F. Muecksch, J. C. C. Lorenzi, S. R. Leist, M. Cipolla, S. Bournazos, F. Schmidt, A. Gazumyan, R. S. Baric, D. F. Robbiani, T. Hatziioannou, J. V. Ravetch, P. D. Bieniasz, M. C. Nussenzweig, T. P. Sheahan
This study evaluates the in vivo protective efficacy of SARS-CoV-2 monoclonal antibodies, finding that in vitro potency does not always predict in vivo activity and that effector function and combinations are critical for protection.
bioRxiv · Sep 15, 2020Microbiology
Z. Wang, J. C. C. Lorenzi, F. Muecksch, S. Finkin, C. Viant, C. Gaebler, M. Cipolla, H.-H. Hoffman, T. Y. Oliveira, D. A. Oren, V. Ramos, L. Nogueira, E. Michailidis, D. F. Robbiani, A. Gazumyan, , M. C. Nussenzweig
This study shows that secretory IgA, particularly dimers, are more potent than IgG in neutralizing SARS-CoV-2 in vitro, suggesting their importance for mucosal protection and vaccine design.
bioRxiv · Sep 9, 2020 · PreprintImmunology
Y. Weisblum, F. Schmidt, F. Zhang, J. DaSilva, D. Poston, J. C. C. Lorenzi, F. Muecksch, M. Rutkowska, H.-H. Hoffmann, E. Michailidis, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, , P. D. Bieniasz
The paper shows SARS-CoV-2 variants resistant to neutralizing antibodies can be selected and are present in circulating populations, suggesting the need for combination antibody therapies.
bioRxiv · Jul 21, 2020Microbiology
F. Schmidt, Y. Weisblum, F. Muecksch, H.-H. Hoffmann, E. Michailidis, J. C. C. Lorenzi, P. Mendoza, M. Rutkowska, E. Bednarski, C. Gaebler, M. Agudelo, A. Cho, Z. Wang, A. Gazumyan, M. Cipolla, , P. D. Bieniasz
The paper describes assays using pseudotyped and chimeric viruses to measure SARS-CoV-2 neutralizing antibody activity, showing correlation with authentic assays.
bioRxiv · Jun 8, 2020Microbiology
C. O. Barnes, A. P. West, K. Huey-Tubman, M. A. G. Hoffmann, N. G. Sharaf, P. R. Hoffman, N. Koranda, H. B. Gristick, C. Gaebler, F. Muecksch, J. C. Cetrulo Lorenzi, S. Finkin, T. Hagglof, A. Hurley, K. G. Millard, , P. J. Bjorkman
bioRxiv · May 28, 2020Immunology
I. Lui, X. X. Zhou, S. A. Lim, S. Elledge, P. Solomon, N. J. Rettko, B. S. Zha, L. L. Kirkemo, J. A. Gramespacher, J. Liu, F. Muecksch, J. C. C. Lorenzi, F. Schmidt, Y. Weisblum, D. F. Robbiani, , J. A. Wells
This study investigates the interaction between SARS-CoV-2 Spike and ACE2, showing that dimeric ACE2 binds with high affinity to Spike and blocks viral entry, with limited intra-Spike avidity.
bioRxiv · May 21, 2020 · PreprintBiochemistry
D. F. Robbiani, C. Gaebler, F. Muecksch, J. Cetrulo Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. Barnes, S. Finkin, T. Hagglof, T. Oliveira, C. Viant, A. Hurley, K. Millard, R. Kost, , Nuss
The paper analyzes antibody responses in convalescent individuals, finding low neutralizing titers but rare potent RBD-specific antibodies with broad antiviral potential.
bioRxiv · May 13, 2020Immunology